Publications by authors named "T Brandenburg"
Article Synopsis
- Scientists are studying a special tool called FAPIs that helps see tumors in the body, especially in autoimmune thyroiditis (AIT), which is a thyroid disease.
- They looked at patients with AIT and noticed that their thyroids were using more FAPIs and glucose in scans compared to healthy people.
- It's important to be careful when interpreting these results because finding thyroid issues in scans could mean patients need more check-ups.
[Thyroid carcinomas: the role of systemic therapies in internal medicine].
Inn Med (Heidelb)
July 2024
Article Synopsis
- The molecular pathogenesis of thyroid carcinoma involves various types originating from follicular cells and C-cells, with differentiated types generally having a good prognosis after surgery and radioiodine therapy.
- When tumors progress and lose iodine uptake ability, treatment shifts towards a watchful waiting approach, while targeted therapies are available for specific mutations like BRAF and RET.
- For advanced cases, especially anaplastic thyroid carcinoma, prompt diagnosis and treatment strategies like surgery, radiochemotherapy, and combination therapies with multityrosine kinase inhibitors and immune checkpoint inhibitors are crucial, emphasizing the need for specialized care centers.
Article Synopsis
- - This study analyzed 683 individuals with various mutations in the RET gene associated with multiple endocrine neoplasia type 2 (MEN 2), focusing on how these mutations impact age-specific disease development.
- - The research found distinct age patterns in the progression from C cell disease to medullary thyroid cancer (MTC), pheochromocytoma, and primary hyperparathyroidism, differing significantly by RET mutation type.
- - Findings suggest that understanding these age-specific development patterns can help in assessing risks and planning targeted monitoring for new RET mutation carriers.
(1) Background: The wider adoption of a preoperative ultrasound and calcitonin screening complemented by an intraoperative frozen section has increased the number of patients with occult sporadic medullary thyroid cancer (MTC). These advances offer new opportunities to reduce the extent of the initial operations, minimizing operative morbidity and the risk of postoperative thyroxin supplementation without compromising the cure. (2) Methods: This systematic review of the international literature published in the English language provides a comprehensive update on the latest progress made in the risk-adapted surgery for sporadic and hereditary MTC guided by an intraoperative frozen section.
View Article and Find Full Text PDFBased on phase III clinical studies, four multi-kinase inhibitors (MKI) are approved for the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma (rrDTC) and medullary thyroid carcinoma (MTC) in Germany. Only recently, based on the randomized trial COSMIC-311, Cabozantinib has been approved as a second-line treatment option in advanced rrDTC. As first in-label selective RET-Inhibitor, Selpercatinib showed promising efficacy in advanced MTC (first line) with RET mutations and rrDTC (second line) with RET fusions along with fewer side effects.
View Article and Find Full Text PDF